
Catalent CTLT
Quarterly report 2024-Q3
added 11-05-2024
Catalent EV/EBITDA Ratio 2011-2026 | CTLT
Annual EV/EBITDA Ratio Catalent
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 22.8 | 23.2 | 21.1 | 16.1 | 15.5 | 13.3 | 13.7 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.2 | 13.3 | 17.9 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-2.97 | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
0.353 | - | 0.86 % | $ 117 M | ||
|
Canopy Growth Corporation
CGC
|
-4.28 | $ 1.07 | -0.47 % | $ 115 M | ||
|
DURECT Corporation
DRRX
|
1.47 | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
-1.77 | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
-18.5 | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
-27.4 | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
4.15 | - | - | $ 142 M | ||
|
Harrow Health
HROW
|
72.8 | $ 38.95 | -27.32 % | $ 1.43 B | ||
|
Cronos Group
CRON
|
-14.5 | $ 2.62 | -0.57 % | $ 1.36 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-6.92 | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
-50.5 | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
51.8 | $ 0.55 | -0.97 % | $ 9.61 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-19.4 | $ 4.5 | -7.02 % | $ 63.3 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-0.0195 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-1.44 | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
0.202 | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
-2.99 | $ 3.52 | -5.26 % | $ 86.3 M | ||
|
Athenex
ATNX
|
-1.1 | - | -23.39 % | $ 1.76 M | ||
|
Organogenesis Holdings
ORGO
|
15.8 | $ 2.86 | -4.67 % | $ 377 M | ||
|
Emergent BioSolutions
EBS
|
7.77 | $ 8.87 | -1.33 % | $ 454 M | ||
|
ProPhase Labs
PRPH
|
9.86 | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
7.11 | $ 11.92 | 1.24 % | $ 847 M | ||
|
Radius Health
RDUS
|
-13.2 | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
-13.7 | $ 0.9 | 0.37 % | $ 21 M | ||
|
Evolus
EOLS
|
-9.74 | $ 4.21 | -1.86 % | $ 261 M | ||
|
Bausch Health Companies
BHC
|
18.6 | $ 5.77 | -3.11 % | $ 2.11 B | ||
|
Lannett Company
LCI
|
-3.47 | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
160 | - | -39.89 % | $ 27.7 M | ||
|
OrganiGram Holdings
OGI
|
-2.79 | $ 1.38 | -3.17 % | $ 402 M | ||
|
Perrigo Company plc
PRGO
|
11.2 | $ 11.38 | -7.97 % | $ 1.58 B | ||
|
Sundial Growers
SNDL
|
-1.27 | $ 1.53 | 0.33 % | $ 3.37 M | ||
|
Pacira BioSciences
PCRX
|
29.6 | $ 22.06 | 3.67 % | $ 1.02 B | ||
|
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
-2.04 | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-1.81 | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
13.4 | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
-2.91 | $ 4.67 | -3.51 % | $ 141 M | ||
|
SCYNEXIS
SCYX
|
-1.32 | $ 0.73 | -2.19 % | $ 34.9 M | ||
|
Solid Biosciences
SLDB
|
-0.17 | $ 5.99 | -3.47 % | $ 244 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-4.16 | $ 2.76 | -2.66 % | $ 3.43 M | ||
|
Tricida
TCDA
|
-3.32 | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
-45.5 | $ 2.26 | 1.0 % | $ 23.6 M | ||
|
Tilray
TLRY
|
-46 | $ 7.37 | -2.97 % | $ 4.55 B | ||
|
Veru
VERU
|
31.2 | $ 2.54 | -3.05 % | $ 343 M | ||
|
Viatris
VTRS
|
10.5 | $ 15.09 | -3.89 % | $ 18.1 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-0.574 | - | - | $ 55.5 M | ||
|
cbdMD
YCBD
|
-2.7 | $ 0.79 | -2.48 % | $ 3.41 M |